[Brentuximab vedotin for Hodgkin´s lymphoma]

Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Urtasun M, Soto N
Record ID 32014000249
Authors' objectives: To assess the available evidence on the efficacy, safety and coverage policy related issues on the use of brentuximab vedotin in patients with Hodgkin´s lymphoma.
Authors' recommendations: The quality of the available evidence to date is very poor and is based on case series reporting interim result measurements and short term follow-up. However, the efficacy data and toxicity profile suggest brentuximab vedotin might be a therapeutic alternative for resistant or relapsing HL patients failing in at least two lines of treatment and in whom HDT/ASCR is contraindicated, or if HDT/ASCR fails.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Hodgkin Disease
  • Brentuximab Vedotin
  • Antineoplastic Agents, Immunological
  • Antibodies, Monoclonal, Humanized
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.